

Prof.Dr. Mustafa ÖZGÜROĞLU

Kişisel Bilgiler

Doğum Yılı: 1964

Doğum Yeri: K.K.T.C

İş Telefonu: [+90 212 414 3017](tel:+902124143017)

Fax Telefonu: [+90 212 414 3017](tel:+902124143017)

E-posta: mozgur@iuc.edu.tr

Diğer E-posta: ozguroglu@gmail.com

Web: <http://avesis.istanbulc.edu.tr/1662/>

Posta Adresi: Cerrahpaşa- Fatih İstanbul

Eğitim Bilgileri

1993 - 1996

Tıpta Yandal Uzmanlık, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji, Türkiye

1988 - 1993

Tıpta Uzmanlık, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları, Türkiye

Yabancı Diller

Fransızca, B1 Orta İngilizce, C1 İleri

Araştırma Alanları

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

Akademik Unvanlar / Görevler

1988 - Devam Ediyor Prof.Dr., İstanbul Üniversitesi, Dahili Bilimler

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.**
Garassino M. C. , Paz-Ares L., Hui R., Faivre-Finn C., Spira A., Planchard D., Özgüroğlu M., Daniel D., Vicente D., Murakami S., et al.
Future oncology (London, England), 2021 (SCI Expanded İndekslerine Giren Dergi)
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.**
Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al.
Lancet (London, England), cilt.397, ss.592-604, 2021 (SCI Expanded İndekslerine Giren Dergi)
- Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.**
Park K., Özgüroğlu M., Vansteenkiste J., Spigel D., Yang J. C. , Bajars M., Ruisi M., Manitz J., Barlesi F.
Lung cancer (Amsterdam, Netherlands), cilt.154, ss.92-98, 2021 (SCI Expanded İndekslerine Giren Dergi)
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an**

update from the PACIFIC trial.

Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F. , Spigel D. R. , Garassino M. C. , Reck M., Senan S., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 (SCI Expanded İndekslerine Giren Dergi)

- V. **The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer.**
Celik E., Samanci N. S. , Karadag M., Demirci N. S. , Demirelli F. H. , Ozguroglu M.
Medical oncology (Northwood, London, England), cilt.38, ss.11, 2021 (SCI Expanded İndekslerine Giren Dergi)
- VI. **Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.**
Lu S., Casarini I., Kato T., Cobo M., Özgüroğlu M., Hodge R., van der Gronde T., Saggese M., Ramalingam S. S.
Clinical lung cancer, 2021 (SCI Expanded İndekslerine Giren Dergi)
- VII. **Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).**
Faivre-Finn C., Spigel D., Senan S., Langer C., Perez B., Özgüroğlu M., Daniel D., Villegas A., Vicente D., Hui R., et al.
Lung cancer (Amsterdam, Netherlands), cilt.151, ss.30-38, 2020 (SCI Expanded İndekslerine Giren Dergi)
- VIII. **Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.**
Moehler M., Dvorkin M., Boku N., Özgüroğlu M., Ryu M., Muntean A., Lonardi S., Nechaeva M., Bragagnoli A., Coşkun H., et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 (SCI Expanded İndekslerine Giren Dergi)
- IX. **Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110**
Herbst R. S. , De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Filip E., Andric Z., et al.
SWISS MEDICAL WEEKLY, 2020 (SCI İndekslerine Giren Dergi)
- X. **Final overall survival analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration resistant prostate cancer and homologous recombination repair (HRR) gene alterations.**
Sandhu S., de Bono J., Mateo J., Fizazi K., Fred S., Shore N., Chi K., Sartor O., Agarwal N., Olmos D., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, cilt.16, ss.41, 2020 (SCI İndekslerine Giren Dergi)
- XI. **Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.**
Herbst R., Giaccone G., de M., Reinmuth N., Vergnenegre A., Barrios C., Morise M., Filip E., Andric Z., Geater S., et al.
The New England journal of medicine, cilt.383, ss.1328-1339, 2020 (SCI Expanded İndekslerine Giren Dergi)
- XII. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes**
Schulz C., Chen Y., Paz-Ares L. G. , Dvorkin M., Trukhin D., Reinmuth N., Garassino M. C. , Statsenko G., Voitko O., Hochmair M. J. , et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.144-145, 2020 (SCI İndekslerine Giren Dergi)
- XIII. **Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study**
Grohe C., Paz-Ares L. G. , Dvorkin M., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , Ozguroglu M., Ji J. H. , et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.149, 2020 (SCI İndekslerine Giren Dergi)
- XIV. **Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.**
Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K., Sartor O., Agarwal N., Olmos D., et al.
The New England journal of medicine, 2020 (SCI Expanded İndekslerine Giren Dergi)
- XV. **PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.**
Huddart R., Siefker-Radtke A., Balar A., Bilen M., Powles T., Bamias A., Castellano D., Khalil M., Van D., Koshkin V., et

al.

Future oncology (London, England), 2020 (SCI Expanded İndekslerine Giren Dergi)

- XVI. **Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.**
Goldman J., Garassino M., Chen Y., Özgüroğlu M., Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J., Hochmair M., et al.
Lung cancer (Amsterdam, Netherlands), cilt.149, ss.46-52, 2020 (SCI Expanded İndekslerine Giren Dergi)
- XVII. **Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer**
Sengul S., Cikman D., Oruc K., Bedir S., Çelik E., Degerli E., Derin S., Demirelli F. H. , Özgüroğlu M.
TUMORI J, 2020 (SCI İndekslerine Giren Dergi)
- XVIII. **Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial**
Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C. , Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., et al.
ANNALS OF ONCOLOGY, cilt.31, sa.6, ss.798-806, 2020 (SCI İndekslerine Giren Dergi)
- XIX. **Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).**
Naidoo J., Vansteenkiste J. F. , Faivre-Finn C., Ozguroglu M., Murakami S., Hui R., Quantin X., Broadhurst H., Newton M., Dennis P. A. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XX. **Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial**
Galsky M. D. , Arranz Arijia J. A. , Bamias A., Davis I. D. , De Santis M., Kikuchi E., Garcia-del-Muro X., De Giorgi U., Mencinger M., Izumi K., et al.
LANCET, cilt.395, sa.10236, ss.1547-1557, 2020 (SCI İndekslerine Giren Dergi)
- XXI. **The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.**
Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Vivaldi C., Olesinski T., Caglevic C., Chung H. C. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XXII. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.**
Chen Y., Paz-Ares L. G. , Dvorkin M., Trukhin D., Reinmuth N., Chiara Garassino M., Statsenko G., Voitko O., Hochmair M., Ozguroglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XXIII. **Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.**
Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., Aksoy S., Tek I., Eralp Y., Mandel N. M. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XXIV. **Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.**
Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., Chung H. C. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XXV. **The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.**
Shitara K., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandal M., Ryu M., Vivaldi C., Olesinski T., Chung H. C. , Muro K., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)

- XXVI. **Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.**
Paz-Ares L. G. , Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M., Ozguroglu M., Ji J. H. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020 (SCI İndekslerine Giren Dergi)
- XXVII. **Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.**
Matsubara N., Chi K., Özgüroğlu M., Rodriguez-Antolin A., Feyerabend S., Fein L., Alekseev B., Suler G., Protheroe A., Li S., et al.
European urology, cilt.77, ss.494-500, 2020 (SCI İndekslerine Giren Dergi)
- XXVIII. **IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC**
Herbst R., De Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C., Morise M., Font E., Andric Z., Geater S., et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, cilt.8, 2020 (SCI İndekslerine Giren Dergi)
- XXIX. **First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC**
Faehling M., Planchard D., Cho B. C. , Gray J. E. , Paz-Ares L. G. , Ozguroglu M., Villegas A. E. , Daniels D. B. , Vicente D., Murakami S., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.120, 2020 (SCI İndekslerine Giren Dergi)
- XXX. **Central, Prospective Detection of Homologous Recombination Repair (HRR) Gene Alteration in Tumor Tissue From > 4000 Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Screened for The Profound Study**
Stenzl A., Hussain M., Fizazi K., Saad F., Shore N., Sandhu S., Mehra N., Kolinsky M., Roubaud G., Ozguroglu M., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.81, 2020 (SCI İndekslerine Giren Dergi)
- XXXI. **Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab +/- Tremelimumab plus Chemotherapy in ES-SCLC**
Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , Ozguroglu M., Li J. H. , Voitko O., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.115, 2020 (SCI İndekslerine Giren Dergi)
- XXXII. **Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC**
Gray J. E. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , Cho B. C. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.15, sa.2, ss.288-293, 2020 (SCI İndekslerine Giren Dergi)
- XXXIII. **Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study**
Hui R., ÖZGÜROĞLU M., Villegas A., Daniel D., Vicente D., Murakami S., Yokoi T., Chiappori A., Lee K. H. , de Wit M., et al.
LANCET ONCOLOGY, cilt.20, sa.12, ss.1670-1680, 2019 (SCI İndekslerine Giren Dergi)
- XXXIV. **Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.**
PAZ-ARES L., DVORKIN M., CHEN Y., REINMUTH N., HOTTA K., TRUKHIN D., STATSENKO G., HOCHMAIR M., Özgüroğlu M., Ji J., et al.
Lancet (London, England), cilt.394, ss.1929-1939, 2019 (SCI İndekslerine Giren Dergi)
- XXXV. **Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.**
AGARWAL N., MCQUARRIE K., BJARTELL A., CHOWDHURY S., PEREIRA D. S. G. A. , CHUNG B., Özgüroğlu M., Juárez S., MERSEBURGER A., UEMURA H., et al.

- The Lancet. Oncology, cilt.20, ss.1518-1530, 2019 (SCI İndekslerine Giren Dergi)
- XXXVI. **2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)**
Barlesi F., Ozguroglu M., Vansteenkiste J., Spigel D., Yang J., Ishii H., Garassino M., de Marinis F., Szczesna A., Polychronis A., et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, cilt.7, 2019 (SCI İndekslerine Giren Dergi)
- XXXVII. **Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study**
Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , Ozguroglu M., Ji J. H. , Voitko O., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI İndekslerine Giren Dergi)
- XXXVIII. **Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.**
CHI K., AGARWAL N., BJARTELL A., CHUNG B., PEREIRA D. S. G. A. , GIVEN R., Juárez S., MERSEBURGER A., Özgüroğlu M., UEMURA H., et al.
The New England journal of medicine, cilt.381, ss.13-24, 2019 (SCI İndekslerine Giren Dergi)
- XXXIX. **Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.**
LEVY B., PAZ-ARES L., BENNOUNA J., FELIP E., ABREU D., ISLA D., BARLESI F., MOLINIER O., MADELAINE J., AUDIGIER-VALETTE C., et al.
Clinical lung cancer, cilt.20, 2019 (SCI İndekslerine Giren Dergi)
- XL. **Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.**
FIZAZI K., TRAN N., FEIN L., MATSUBARA N., RODRIGUEZ-ANTOLIN A., ALEKSEEV B., Özgüroğlu M., YE D., FEYERABEND S., PROTHEROE A., et al.
The Lancet. Oncology, cilt.20, ss.686-700, 2019 (SCI İndekslerine Giren Dergi)
- XLI. **KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.**
KATO K., SHAH M., ENZINGER P., BENNOUNA J., SHEN L., ADENIS A., SUN J., CHO B., Özgüroğlu M., KOJIMA T., et al.
Future oncology (London, England), cilt.15, ss.1057-1066, 2019 (SCI İndekslerine Giren Dergi)
- XLII. **TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)**
Merseburger A. S. , Chowdhury S., Agarwal N., Bjartell A., Chung B. H. , Pereira de Santana Gomes A. J. , Given R. W. , Soto A. J. , Ozguroglu M., Uemura H., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.42, ss.286, 2019 (SCI İndekslerine Giren Dergi)
- XLIII. **Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.**
ANTONIA S., VILLEGAS A., DANIEL D., VICENTE D., MURAKAMI S., HUI R., KURATA T., CHIAPPORI A., LEE K., de W., et al.
The New England journal of medicine, cilt.379, ss.2342-2350, 2018 (SCI İndekslerine Giren Dergi)
- XLIV. **Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study**
Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., Ozguroglu M., Szczesna A., Polychronis A., Uslu R., et al.
LANCET ONCOLOGY, cilt.19, sa.11, ss.1468-1479, 2018 (SCI İndekslerine Giren Dergi)
- XLV. **PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT**
Vansteenkiste J., Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., Murakami S., Hui R., Lee K., Cho B. C. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)
- XLVI. **Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.**

JERUSALEM G., de B., HURVITZ S., YARDLEY D., KOVALENKO E., EJLERTSEN B., BLAU S., Özgüroglu M., LANDHERR L., EWERTZ M., et al.

JAMA oncology, cilt.4, ss.1367-1374, 2018 (SCI İndekslerine Giren Dergi)

XLVII. Effect of Induction Chemotherapy in the PACIFIC Study

Spigel D., Vansteenkiste J., Reck M., Wakelee H., Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., Murakami S., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)

XLVIII. Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., De Marinis F., Ozguroglu M., Szczesna A., Polychronis A., Uslu R., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)

XLIX. Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC

Socinski M., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Gray J., Park K., Vincent M., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)

L. Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC

Antonia S., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , De Wit M., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)

LI. Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Spira A., Planchard D., Cho B. C. , Ozguroglu M., Daniel D., Villegas A., Vicente D., Hui R., Murakami S., Paz-Ares L., et al.

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.10, 2018 (SCI İndekslerine Giren Dergi)

LII. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J. , LAINEZ N., GONZALEZ I., CASTELLANO D. E. , Ozguroglu M., GARCIA CARBONERO I., FLECHON A., et al.

CLINICAL GENITOURINARY CANCER, cilt.16, sa.4, 2018 (SCI İndekslerine Giren Dergi)

LIII. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA K., Ozguroglu M., BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., FORNARO L., OLESINSKI T., CAGLEVIC C., CHUNG H. C. , et al.

LANCET, cilt.392, sa.10142, ss.123-133, 2018 (SCI İndekslerine Giren Dergi)

LIV. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M., AZEVEDO S. J. , CRUZ F. M. , DEBLED M., Hegg R., TOYAMA T., FALKSON C., et al.

JAMA ONCOLOGY, cilt.4, sa.7, ss.977-984, 2018 (SCI İndekslerine Giren Dergi)

LV. Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.

Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., Chung H. C. , et al.

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)

LVI. Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung

Levy B. P. , Paz-Ares L. G. , Bennouna J., Felip E., Abreu D. R. , Isla D., Barlesi F., Molinier O., Madelaine J., Audigier-Valette C., et al.

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)

LVII. Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

Jerusalem G. H. M. , Kovalenko E., Yardley D. A. , De Boer R. H. , Hurvitz S. A. , Ejlersen B., Blau S., Ozguroglu M., Landherr L., Ewertz M., et al.

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)

- LVIII. **Subsequent treatment after abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.**
Chi K. N. , Namphuong Tran N. T. , Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E.
JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)
- LIX. **Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.**
Fizazi K., Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E. , Antolin A. R. , Alekseev B. Y. , Sulur G., Protheroe A., De Porre P., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)
- LX. **Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes**
Hui R., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., Ryden A., Zhang Y., Dennis P., Antonia S.
JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.4, 2018 (SCI İndekslerine Giren Dergi)
- LXI. **Durvalumab in Stage III Non-Small-Cell Lung Cancer REPLY**
Antonia S. J. , Ozguroglu M.
NEW ENGLAND JOURNAL OF MEDICINE, cilt.378, sa.9, ss.869-870, 2018 (SCI İndekslerine Giren Dergi)
- LXII. **Durvalumab in Stage III Non-Small-Cell Lung Cancer.**
Antonia S., Özgüroğlu M.
The New England journal of medicine, cilt.378, ss.869-870, 2018 (SCI İndekslerine Giren Dergi)
- LXIII. **Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial**
Martin M., Holmes F. A. , Ejlersen B., Delalogue S., Moy B., Iwata H., von Minckwitz G., Chia S. K. L. , Mansi J., Barrios C. H. , et al.
The Lancet Oncology, cilt.18, sa.12, ss.1688-1700, 2017 (SCI İndekslerine Giren Dergi)
- LXIV. **Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC**
Hui R., Ozguroglu M., Daniel D., Baz D., Murakami S., Yokoi T., Chiappori A., Lee K. H. , De Wit M., Cho B. C. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.12, sa.11, 2017 (SCI İndekslerine Giren Dergi)
- LXV. **Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer**
Antonia S. J. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H. , de Wit M., et al.
NEW ENGLAND JOURNAL OF MEDICINE, cilt.377, sa.20, ss.1919-1929, 2017 (SCI İndekslerine Giren Dergi)
- LXVI. **LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naïve prostate cancer (mHNPC)**
Feyerabend S., Tran N., Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B., Ozguroglu M., Ye D., Protheroe A., De Porre P., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.40, ss.113, 2017 (SCI İndekslerine Giren Dergi)
- LXVII. **Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer**
Fizazi K., NamPhuong Tran N. T. , Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B. Y. , Ozguroglu M., Ye D., Feyerabend S., Protheroe A., et al.
NEW ENGLAND JOURNAL OF MEDICINE, cilt.377, sa.4, ss.352-360, 2017 (SCI İndekslerine Giren Dergi)
- LXVIII. **LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naïve prostate cancer.**
Fizazi K., Namphuong Tran N. T. , Enrique Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B. Y. , Ozguroglu M., Ye D., Feyerabend S., Protheroe A., et al.

- JOURNAL OF CLINICAL ONCOLOGY, cilt.35, sa.18, 2017 (SCI İndekslerine Giren Dergi)
- LXXIX. **Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study**
Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., Caty A., Dujardin C., Auclin E., Thibaut C., et al.
CLINICAL GENITOURINARY CANCER, cilt.15, sa.3, 2017 (SCI İndekslerine Giren Dergi)
- LXX. **COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY**
Altundag K., Basaran G., Oksuzoglu B., Oven B., Ozguroglu M., Aydin D., Hacibedel B., Helvacioglu K., Tuna E., Tatar M.
VALUE IN HEALTH, cilt.19, sa.3, 2016 (SCI İndekslerine Giren Dergi)
- LXXI. **Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?**
Ozturk M. A. , DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., Buyukunal E., Ozguroglu M., Turna H., Erdamar S., et al.
Hepato-Gastroenterology, cilt.62, sa.137, ss.59-64, 2015 (SCI Expanded İndekslerine Giren Dergi)
- LXXII. **Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer**
Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzebec P., Massard C., et al.
EUROPEAN JOURNAL OF CANCER, cilt.50, sa.9, ss.1602-1609, 2014 (SCI İndekslerine Giren Dergi)
- LXXIII. **Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial**
Andre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., Masuda N., Wilks S., Arena F., Isaacs C., et al.
LANCET ONCOLOGY, cilt.15, sa.6, ss.580-591, 2014 (SCI İndekslerine Giren Dergi)
- LXXIV. **Receptor expression discrepancy between primary and metastatic breast cancer lesions**
Ozen D. S. K. , Öztürk M. S. , Aydin O., Turna Z. H. , Ilvan Ş., Ozguroglu M.
Oncology Research and Treatment, cilt.37, sa.11, ss.622-626, 2014 (SCI Expanded İndekslerine Giren Dergi)
- LXXV. **Quality-of-life in Turkish cancer patients: The impact of sociodemographic characteristics, medical history, and management Türk kanser hastaları{dotless}nda sosyodemografik karakteristiklerin, ti{dotless}bbi öykünün ve tedavilerin yaşam kalitesi üzerine etkisi**
Toptas T., Yildiz I., Yildiz M., Varol U., Bayoglu I. V. , Ozguroglu M.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, cilt.24, sa.1, ss.23-29, 2014 (SCI Expanded İndekslerine Giren Dergi)
- LXXVI. **BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine**
Isaacs C., Ozguroglu M., Jerusalem G., Xu B., Lang I., O'Regan R., White M., Fasolo A., Litton J., Toi M., et al.
CANCER RESEARCH, cilt.73, 2013 (SCI İndekslerine Giren Dergi)
- LXXVII. **Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series**
Saygin C., Uzunaslani D., Ozguroglu M., Senocak M., Tuzuner N.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.88, sa.2, ss.253-271, 2013 (SCI İndekslerine Giren Dergi)
- LXXVIII. **Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial**
Jerusalem G., Andre F., Chen D., Robinson D., Ozguroglu M., Lang I., White M., Toi M., Taran T., Gianni L.
EUROPEAN JOURNAL OF CANCER, cilt.49, 2013 (SCI İndekslerine Giren Dergi)
- LXXIX. **Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial**
Bahl A., Oudard S., Tombal B., Ozguroglu M., Hansen S., Kocak I., Gravis G., Devin J., Shen L., de Bono J. S. , et al.
ANNALS OF ONCOLOGY, cilt.24, sa.9, ss.2402-2408, 2013 (SCI İndekslerine Giren Dergi)
- LXXX. **Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience**
Selcukbiricik F., Buyukunal E., Tural D., Ozguroglu M., Demirelli F., Serdengeci S.
WORLD JOURNAL OF GASTROENTEROLOGY, cilt.19, sa.14, ss.2154-2161, 2013 (SCI İndekslerine Giren Dergi)

- LXXXI. **Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer**
Tural D., Ozturk M., Selcukbiricik F., Yildiz O., Elicin O., Turna H., Guney S., Ozguroglu M.
JOURNAL OF BUON, cilt.18, sa.2, ss.385-390, 2013 (SCI İndekslerine Giren Dergi)
- LXXXII. **Patterns of complementary and alternative medicine use among turkish cancer patients**
Yildiz I., Ozguroglu M., TOPTAŞ T., Turna H., Sen F., Yildiz M.
Journal of Palliative Medicine, cilt.16, sa.4, ss.383-390, 2013 (SCI Expanded İndekslerine Giren Dergi)
- LXXXIII. **The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer**
Selcukbiricik F., Erdamar S., Ozkurt C. U. , Mandel N. M. , Demirelli F. H. , Ozguroglu M., Tural D., Buyukunal E., Serdengeci S.
JOURNAL OF BUON, cilt.18, sa.1, ss.116-123, 2013 (SCI İndekslerine Giren Dergi)
- LXXXIV. **Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey**
SELÇUKBİRİCİK F., Tural D., Bilici A., Uzel E. K. , Ozguroglu M., Demirelli F., Buyukunal E., Serdengeci S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.14, sa.1, ss.553-556, 2013 (SCI İndekslerine Giren Dergi)
- LXXXV. **Primary osteosarcoma of the heart: Experience of an unusual case**
Özen D. S. K. , Öztürk M. A. , Selcukbiricik F., Esatoglu S. N. , Turna Z. H. , Beyaz P., Dervisoglu S., Özgüroglu M.
Case Reports in Oncology, cilt.6, sa.1, ss.224-228, 2013 (SCI Expanded İndekslerine Giren Dergi)
- LXXXVI. **Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial**
Ramlau R., Gorbunova V., Ciuleanu T. E. , Novello S., Ozguroglu M., GÖKSEL T., Baldotto C., Bennouna J., Shepherd F. A. , Le-Guenec S., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.30, sa.29, ss.3640-3647, 2012 (SCI İndekslerine Giren Dergi)
- LXXXVII. **Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain**
Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.
ONKOLOGIE, cilt.35, sa.5, ss.254-258, 2012 (SCI İndekslerine Giren Dergi)
- LXXXVIII. **Prognostic factors for survival in the phase III TROPIC trial.**
Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Kocak I., Gravis G., Bodrogi I., MacKenzie M. J. , Orlandi F. J. , et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.30, sa.5, 2012 (SCI İndekslerine Giren Dergi)
- LXXXIX. **Synchronous detection of hairy cell leukemia and HIV-negative Kaposi's sarcoma of the lymph node: A diagnostic challenge and a rare coincidence**
Aydin S. O. , Eskazan A. E. , Aki H., Ozguroglu M., Baslar Z., Soysal T.
Case Reports in Oncology, cilt.4, sa.3, ss.439-444, 2011 (SCI Expanded İndekslerine Giren Dergi)
- XC. **AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)**
Novello S., Ramlau R., Gorbunova V. A. , Ciuleanu T. E. , Ozguroglu M., GÖKSEL T., Baldotto C., Bennouna J., Shepherd F. A. , Scagliotti G.
JOURNAL OF THORACIC ONCOLOGY, cilt.6, sa.6, 2011 (SCI İndekslerine Giren Dergi)
- XCI. **Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.**
Ozguroglu M., Oudard S., Sartor A. O. , Hansen S., Machiels J. H. , Shen L., De Bono J. S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XCII. **Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.**
Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., De Bono J. S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)
- XCIII. **A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and**

survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

De Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., Sartor A. O.

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI İndekslerine Giren Dergi)

- XCIV. **Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study**
Ozguroglu M., Oudard S., Sartor A. O. , Hansen S., Machiels J. H. , Shen L., De Bono J. S.
JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.7, 2011 (SCI İndekslerine Giren Dergi)
- XCIV. **CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT**
Tombal B., Oudard S., Ozguroglu M., Hansen S., Kocak I., Gravis G., Sartor A. O. , Shen L., de Bono J. S.
EUROPEAN UROLOGY SUPPLEMENTS, cilt.10, sa.2, ss.335-336, 2011 (SCI İndekslerine Giren Dergi)
- XCVI. **Gastroenteropancreatic Neuroendocrine tumors: 10-Year experience in a single center**
Yildiz O., Ozguroglu M., Yanmaz T., Turna H., Serdengeçti S., Dogusoy G.
Medical Oncology, cilt.27, sa.4, ss.1050-1056, 2010 (SCI Expanded İndekslerine Giren Dergi)
- XCVII. **Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case**
Bilici A., Ozguroglu M., Tuzuner N., Goksel S., Turna H.
Archives of Gynecology and Obstetrics, cilt.282, sa.5, ss.587-590, 2010 (SCI Expanded İndekslerine Giren Dergi)
- XCVIII. **Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial**
de Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., Gravis G., Bodrogi I., Mackenzie M. J. , Shen L., et al.
LANCET, cilt.376, sa.9747, ss.1147-1154, 2010 (SCI İndekslerine Giren Dergi)
- XCIX. **Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)**
De Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., Matthews P., Sartor A. O.
JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi)
- C. **Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain**
Dizdar O., Altundag M. K. , Ozkok S., Ozsaran Z., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi)
- CI. **How does (18)f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?**
Selcukbiricik F., Ozguroglu M., Ozturk M. A. , Ozgur N., Turna H., Tural D., Hallac M., Demirkiran F., Arvas M., Mandel N. M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi)
- CII. **Surgery for isolated liver metastasis of ovarian cancer**
Pekmezci S., Saribeyoglu K., Aytac E., Arvas M., Demirkiran F., Ozguroglu M.
Asian Journal of Surgery, cilt.33, sa.2, ss.83-88, 2010 (SCI Expanded İndekslerine Giren Dergi)
- CIII. **The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpaşa experience Mide karsinomlarında postoperatif kemoradyoterapi tedavi sonuçları: Cerrahpaşa deneyimi**
Çolpan Öksüz D., Eren M. F. , Şenel Beşe N., Büyükuşal E., Özgüroğlu M., Molinas Mandel N., Turna H., Demirelli F., Serdengeçti S., Atkovar G., et al.
Turk Onkoloji Dergisi, cilt.25, sa.1, ss.1-10, 2010 (SCI Expanded İndekslerine Giren Dergi)
- CIV. **Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. "**
TURNA Z. H. , ÖZGÜROĞLU M., BOLAYIRLI İ. M. , ORHANOĞLU T., BALCI H.

- CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.15, ss.454-457, 2009 (SCI Expanded İndekslerine Giren Dergi)
- CV. **Is there any effect of tumor burden on hemostatic parameters in cancer patients? a case&E"control study of hemostatic abnormalities and anticardiolipin antibodies in solid tumors**
Turna H., Ozguroglu M., Bolayirli M., Orhanoglu T., Balci H.
Clinical and Applied Thrombosis/Hemostasis, cilt.15, sa.4, ss.454-457, 2009 (SCI Expanded İndekslerine Giren Dergi)
- CVI. **Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case–Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors**
TURNA Z. H. , ÖZGÜROĞLU M., BOLAYIRLI İ. M. , ORHANOĞLU T., BALCI H.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.15, sa.4, ss.454-457, 2009 (SCI İndekslerine Giren Dergi)
- CVII. **Metastasis from breast carcinoma to endometrial polyp**
Aydin O., Bagci P., Akyildiz E. U. , Ozguroglu M., Ilvan Ş.
European Journal of Gynaecological Oncology, cilt.29, sa.6, ss.666-668, 2008 (SCI Expanded İndekslerine Giren Dergi)
- CVIII. **Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: A comparative study**
Yilmaz M. H. , Ozguroglu M., Mert D., Turna H., Demir G., Adaletli I., Ulus S., Halac M., Kanberoglu K.
Medical Oncology, cilt.25, sa.3, ss.257-263, 2008 (SCI Expanded İndekslerine Giren Dergi)
- CIX. **Determining predominating histologic component in malignant mixed müllerian tumors: Is it worth it?**
Ozguroglu M., Bilici A., Ilvan Ş., Turna H., Atalay B., Mandel N., Sahinler I.
International Journal of Gynecological Cancer, cilt.18, sa.4, ss.809-812, 2008 (SCI Expanded İndekslerine Giren Dergi)
- CX. **A case-control study of non-alcoholic fatty liver disease in breast cancer**
Bilici A., Ozguroglu M., Mihmanh I., Turna H., Adaletli I.
Medical Oncology, cilt.24, sa.4, ss.367-371, 2007 (SCI Expanded İndekslerine Giren Dergi)
- CXI. **Neuroblastoma in adults, presentation of 2 cases**
Demir H., Aydin O., Durak H., Dervisoglu S., Ozguroglu M., Sahinler I.
VIRCHOWS ARCHIV, cilt.451, sa.2, ss.577, 2007 (SCI İndekslerine Giren Dergi)
- CXII. **Thymoma with chronic diarrhea: Report of two cases and review of the literature**
Yildiz O., Ozguroglu M., TURNA H., YANMAZ T., Kaynak K., Akman C., CETIN S. E. , Oz B., ÇELİK A.
Medical Oncology, cilt.24, sa.1, ss.119-123, 2007 (SCI Expanded İndekslerine Giren Dergi)
- CXIII. **Paraneoplastic pemphigus associated with fludarabine use**
Yıldız O., Özgüroğlu M., Yanmaz M. R. , Turna H., Kursunoglu S. G. , Antonov M., Serdaroglu S., Demirkesen C., Büyükkunal E.
Medical Oncology, cilt.24, sa.1, ss.115-118, 2007 (SCI Expanded İndekslerine Giren Dergi)
- CXIV. **The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy**
Yilmaz M. H. , Esen G., Ayarcan Y., Aydogan F., Ozguroglu M., Demir G., Bese N., Mandel N. M.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, cilt.13, sa.1, ss.13-18, 2007 (SCI İndekslerine Giren Dergi)
- CXV. **C-reactive protein as an acute phase protein in cancer patients**
Bolayirli M., Turna H., ORHANOĞLU T., Ozaras R., İLHAN M., Ozguroglu M.
Medical Oncology, cilt.24, sa.3, ss.338-344, 2007 (SCI Expanded İndekslerine Giren Dergi)
- CXVI. **Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer [1]**
Ozguroglu M., Yildiz O., Turna H., Kadioglu P.
Gynecologic Oncology, cilt.101, sa.1, ss.183, 2006 (SCI Expanded İndekslerine Giren Dergi)
- CXVII. **Devastating effects of chemotherapy: Deafness and acute renal failure in a patient with epithelial ovarian cancer**
Ozguroglu M., Sari O., Turna H.
International Journal of Gynecological Cancer, cilt.16, ss.394-396, 2006 (SCI Expanded İndekslerine Giren Dergi)
- CXVIII. **Small cell carcinoma of the bladder: A case report and review of the literature**

- Tunc B., Ozguroglu M., Demirkesen O., Alan C., Durak H., Dinçbas F. O. , Kural A. R.
International Urology and Nephrology, cilt.38, sa.1, ss.15-19, 2006 (SCI Expanded İndekslerine Giren Dergi)
- CXIX. **Adult paratesticular myxofibrosarcoma: report of a rare entity and review of the literature.**
OZKAN B., OZGÜROĞLU M., Ozkara H., DURAK H., TALAT Z.
International urology and nephrology, cilt.38, ss.5-7, 2006 (SCI İndekslerine Giren Dergi)
- CXX. **Toxicity and survival results of a phase II study investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma**
Bese N., Buyukunal E., Ozguroglu M., Demir G., Yildirim A., Mandel N. K. , Demirelli F. H. , Serdengeçti S., Ober A.
STRAHLENTHERAPIE UND ONKOLOGIE, cilt.181, sa.10, ss.652-659, 2005 (SCI İndekslerine Giren Dergi)
- CXXI. **Acute phase proteins in malignancy: role of CRP in the discrimination of infectious complications in cancer patients**
Ozguroglu M., Bolayirli M., Orhanoglu T., Yildiz O., Turna H., Serdengeçti S.
EJC SUPPLEMENTS, cilt.3, sa.2, ss.70, 2005 (SCI İndekslerine Giren Dergi)
- CXXII. **Idiopathic thrombocytopenia associated with dysgerminoma in a patient with androgen insensitivity syndrome**
Yildiz O., Ozguroglu M.
GYNECOLOGIC ONCOLOGY, cilt.99, sa.1, ss.248, 2005 (SCI İndekslerine Giren Dergi)
- CXXIII. **Secretory carcinoma of the breast. Case report and review of the literature**
Ozguroglu M., Tascilar K., Ilvan S., Soybir G., Celik V.
Oncology, cilt.68, ss.263-268, 2005 (SCI Expanded İndekslerine Giren Dergi)
- CXXIV. **Delayed onset bleomycin-induced pneumonitis**
Uzel I., Ozguroglu M., Uzel B., Kaynak K., Demirhan O., Akman C., Oz F., Yaman M.
UROLOGY, cilt.66, sa.1, 2005 (SCI İndekslerine Giren Dergi)
- CXXV. **Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: An experimental study**
Yüceyar S., ERTÜRK Ş. M. , Temiz M., Doğusoy G., Gümüştas K., Özgüroğlu M., Cengiz A., Kafadar Y.
Techniques in Coloproctology, cilt.9, sa.3, ss.201-205, 2005 (SCI Expanded İndekslerine Giren Dergi)
- CXXVI. **Does the incidence of anal canal cancers differ in Moslem societies?**
Yumuk P., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, cilt.20, sa.1, ss.76, 2005 (SCI İndekslerine Giren Dergi)
- CXXVII. **Rituximab-induced tumor progression: Does it really happen?**
Ozguroglu M., Turna H.
Medical Oncology, cilt.21, sa.2, ss.205-206, 2004 (SCI Expanded İndekslerine Giren Dergi)
- CXXVIII. **Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma**
Ozguroglu M., Bilici A., Turna H., Serdengeçti S.
Medical Oncology, cilt.21, sa.1, ss.67-72, 2004 (SCI Expanded İndekslerine Giren Dergi)
- CXXIX. **Do we really benefit from checking tumor markers in detecting recurrence in gastrointestinal cancer?**
Ozguroglu M., Turna H.
Journal of B.U.ON., cilt.9, sa.2, ss.179-182, 2004 (SCI Expanded İndekslerine Giren Dergi)
- CXXX. **Acute leukemia in a patient with ocular melanoma - Is it induced by Intraocular Brachytherapy or only a bad fate?**
Ozguroglu M., Bese N., Karacam S., Pazarli H.
MEDICAL ONCOLOGY, cilt.21, sa.4, ss.373-374, 2004 (SCI İndekslerine Giren Dergi)
- CXXXI. **Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women**
Ozguroglu M., Avci B., Turna H., Esen G., Arun B., Celik V., Serdengeçti S.
Medical Oncology, cilt.21, sa.2, ss.139-143, 2004 (SCI Expanded İndekslerine Giren Dergi)
- CXXXII. **Mismanagement of cancer pain: Attitudes of physicians and perception of pain and its treatment by the cancer patients**
Serdengeçti S., Ozguroglu M., Toptas T., Velet M., Yanmaz T., Buyukunal E.

- ANNALS OF ONCOLOGY, cilt.15, ss.211-212, 2004 (SCI İndekslerine Giren Dergi)
- CXXXIII. **Multiple primary tumors in cancer patients in a Turkish population**
Ozguroglu M., Donmez H., Turna H., Mandel N.
ANNALS OF ONCOLOGY, cilt.15, ss.149, 2004 (SCI İndekslerine Giren Dergi)
- CXXXIV. **Intrathoracic extravasation of antineoplastic agents - Case report and systematic review**
Bozkurt A., Uzel B., Akman C., Ozguroglu M., Mandel N.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.26, sa.2, ss.121-123, 2003 (SCI İndekslerine Giren Dergi)
- CXXXV. **Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature.**
Aki H., BASLAR Z., UYGUN N., OZGUROGLU M., TUZUNER N.
Urology, cilt.60, ss.345, 2002 (SCI Expanded İndekslerine Giren Dergi)
- CXXXVI. **Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.**
Altıparmak M. R. , Bilici A., Kisacik B., Ozguroglu M.
Medical oncology (Northwood, London, England), cilt.19, sa.2, ss.117-9, 2002 (SCI Expanded İndekslerine Giren Dergi)
- CXXXVII. **Simultaneous presentation of hepatocellular carcinoma in identical twin brothers**
Demir G., Belentepe S., Ozguroglu M., Celik A., Sayhan N., Tekin S., Mandel N., Buyukunal E., Serdengeçti S.
MEDICAL ONCOLOGY, cilt.19, sa.2, ss.113-116, 2002 (SCI İndekslerine Giren Dergi)
- CXXXVIII. **Metastatic cardiac myxoma**
KAYNAK K., BESIRLI K., ARSLAN C., OZGUROGLU M., Oz B.
ANNALS OF THORACIC SURGERY, cilt.72, sa.2, ss.623-625, 2001 (SCI İndekslerine Giren Dergi)
- CXXXIX. **Serum erythropoietin level in anemic cancer patients**
Ozguroglu M., Arun B., Demir G., Demirelli F. H. , Mandell N., Buyukunal E., Serdengeçti S., Berkarda B.
MEDICAL ONCOLOGY, cilt.17, sa.1, ss.29-34, 2000 (SCI İndekslerine Giren Dergi)
- CXL. **Vinorelbine plus infusional 5-fluorouracil in anthracycline and taxane refractory metastatic breast cancer: A pilot study**
Ozguroglu M., Demir G., Demirelli F., Molinas Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.
Journal of B.U.ON., cilt.4, sa.4, ss.367-372, 1999 (SCI Expanded İndekslerine Giren Dergi)
- CXLI. **Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma**
Ozguroglu M., Turna H., Demir G., Doventas A., Demirelli F. H. , Mandel N. K. , Buyukunal E., Serdengeçti S., Berkarda B.
American Journal of Clinical Oncology: Cancer Clinical Trials, cilt.22, sa.6, ss.615-618, 1999 (SCI Expanded İndekslerine Giren Dergi)
- CXLII. **Paraneoplastic hyperpigmentation secondary to lung cancer resolving after chemotherapy**
Ozguroglu M., Tahan V., Ozguroglu E., Ozaras R., Demir G.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.22, sa.5, ss.533-534, 1999 (SCI İndekslerine Giren Dergi)
- CXLIII. **Anorectal melanoma metastatic to the breast**
Ozguroglu M., Ozaras R., Tahan V., Demirkesen C., Demir G., Dogusoy G., Buyukunal E., Serdengeçti S., Berkarda B.
JOURNAL OF CLINICAL GASTROENTEROLOGY, cilt.29, sa.2, ss.197-199, 1999 (SCI İndekslerine Giren Dergi)
- CXLIV. **Chemoimmunotherapy protocol for advanced gastric cancer**
Demir G., Ozguroglu M., Molinas-Mandel N., Relli F., Buyukunal E., Serdengeçti S., Berkarda B.
EUROPEAN JOURNAL OF CANCER, cilt.35, 1999 (SCI İndekslerine Giren Dergi)
- CXLV. **Serum erythropoietin level in anemic cancer patients**
Ozguroglu M., Demir G., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.
EUROPEAN JOURNAL OF CANCER, cilt.35, 1999 (SCI İndekslerine Giren Dergi)
- CXLVI. **Role of mammographic screening in ovarian cancer**
Ozguroglu M., Esen G., Yildirim B., Demir G., Turna H., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.
EUROPEAN JOURNAL OF CANCER, cilt.35, 1999 (SCI İndekslerine Giren Dergi)
- CXLVII. **Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric**

carcinoma

Ozguroglu M., Demir G.

CANCER, cilt.86, sa.3, ss.547-549, 1999 (SCI İndekslerine Giren Dergi)

CXLVIII. Bilateral inflammatory breast metastases of epithelial ovarian cancer

Ozguroglu M., Ersavasti G., Ilvan S., Hatemi G., Demir G., Demirelli F. H.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.22, sa.4, ss.408-410, 1999 (SCI İndekslerine Giren Dergi)

CXLIX. Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)

Demir G., Ozguroglu M., Sayhan N., Molinas-Mandel N., Demirelli F. H. , Buyukunal E., Tuzuner N., Serdengeçti S., Berkarda B.

ANTICANCER RESEARCH, cilt.19, ss.3517-3520, 1999 (SCI İndekslerine Giren Dergi)

CL. Serum cardiopilin antibodies in cancer patients with thromboembolic events

Ozduroglu M., Arun B., Erzin Y., Demir G., Demirelli F., Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.5, sa.3, ss.181-184, 1999 (SCI İndekslerine Giren Dergi)

CLI. Primary splenic tuberculosis in a patient with nasal angiocentric lymphoma - Mimicking metastatic tumor on abdominal CT

Ozguroglu M., Celik A. F. , Demir G., Aki H., Demirelli F. H. , Mandel N. K. , Buyukunal E., Serdengeçti S., Berkarda B.

JOURNAL OF CLINICAL GASTROENTEROLOGY, cilt.29, sa.1, ss.96-98, 1999 (SCI İndekslerine Giren Dergi)

CLII. Microangiopathic hemolytic anemia as an early predictor of recurrence in gastric cancer

Ozguroglu M., Demirelli F. H. , Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.22, sa.2, ss.214, 1999 (SCI İndekslerine Giren Dergi)

CLIII. Anaphylaxis from intraperitoneal infusion of cisplatin - A case report

Ozguroglu M., Demir G., Demirelli F. H. , Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.22, sa.2, ss.172-173, 1999 (SCI İndekslerine Giren Dergi)

CLIV. Unusual manifestations of B-cell disorders - Case 1: Multiple myeloma with predominant phalangeal involvement

Ozguroglu M., Aki H., Demir G., Demirelli F. H. , Mandel N. K.

JOURNAL OF CLINICAL ONCOLOGY, cilt.17, sa.3, ss.1083-1084, 1999 (SCI İndekslerine Giren Dergi)

CLV. Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma

Özgüroglu M., Ersavasti G. E. , Demir G., Aki H., Demirelli F., Kanberoglu K., Mandel N., Büyükuñal E., Serdengeçti S., Berkarda B.

Pathology and Oncology Research, cilt.5, sa.2, ss.123-128, 1999 (SCI Expanded İndekslerine Giren Dergi)

CLVI. Anaplastic large cell lymphoma of the duodenum fistulized to the colon: Leukocyte common antigen negativity leading to misdiagnosis as carcinoma

Ozguroglu M., Demir G., Dogysoy G., Korman U., Demirelli F., Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.

Journal of B.U.ON., cilt.4, sa.2, ss.215-217, 1999 (SCI Expanded İndekslerine Giren Dergi)

CLVII. Self expanding metal stents for palliation of dysphagia due to esophageal malignancies

Dobrucali A., Ozguroglu M., Demir G., Karahasanoglu T., Uzunismail H., Cebeci H., Oktay E., Dinc I.

Turkish Journal of Gastroenterology, cilt.10, sa.1, ss.18-23, 1999 (SCI Expanded İndekslerine Giren Dergi)

CLVIII. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

Ieli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A., Ozguroglu M., Tas F., Akbulut H., Firat D.

CANCER, cilt.83, sa.12, ss.2475-2480, 1998 (SCI İndekslerine Giren Dergi)

CLIX. Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma

Demir G., Demirelli F., Ozguroglu M., Molinas-Mandel N., Buyukunal E., Tuzuner N., Serdengeçti S., Berkarda B.

INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, cilt.14, sa.3, ss.163-168, 1998 (SCI İndekslerine Giren Dergi)

CLX. High dose epirubicin and cisplatin induction chemotherapy sequentially followed by ifosfamide and

etoposide chemotherapy in extensive stage small cell lung cancer (ES-SCLC)

Demirkazik A., Onat H., Saip P., Ozguroglu M., Kars A., Cay F., Demir G., Uner A., Arpacı F., Aktan G.
ANNALS OF ONCOLOGY, cilt.9, ss.105, 1998 (SCI İndekslerine Giren Dergi)

CLXI. Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma

Ozguroglu E., Buyulbabani N., Ozguroglu M., Baykal C.
BRITISH JOURNAL OF DERMATOLOGY, cilt.137, sa.3, ss.422-425, 1997 (SCI İndekslerine Giren Dergi)

CLXII. Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma

Ozguroglu M., Ersavasti G., Demir G., Demirelli F., Tuzuner N., Kanberoglu K., Mandel N., Buyukunal E., Serdengeçti S.

EUROPEAN JOURNAL OF CANCER, cilt.33, ss.1220, 1997 (SCI İndekslerine Giren Dergi)

CLXIII. NORADRENERGIC AND SEROTONINERGIC DEPRESSION

YAZICI O., ARICIOGLU F., GURVIT G., UCOK A., TASTABAN Y., CANBERK O., OZGUROGLU M., DURAT T., SAHIN D.
JOURNAL OF AFFECTIVE DISORDERS, cilt.27, sa.2, ss.123-129, 1993 (SCI İndekslerine Giren Dergi)

CLXIV. Spontaneous improvement of tardive dystonia during mania

Yazici O., Kantemir E., Tastaban Y., Uçok A., Ozguroglu M.

British Journal of Psychiatry, cilt.158, ss.847-850, 1991 (SSCI İndekslerine Giren Dergi)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.**
Goldman J., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M., Özgüroğlu M., Ji J., et al.
The Lancet. Oncology, 2020 (ESCI İndekslerine Giren Dergi)
- II. **CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab +/- Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab +/- Tremelimumab**
Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J., Ozguroglu M., Li H. J., Voitko O., et al.
PNEUMOLOGIE, cilt.74, 2020 (ESCI İndekslerine Giren Dergi)
- III. **Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry**
Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., Leung K. C., Butt M., Silva A., Castillo L., et al.
JOURNAL OF GLOBAL ONCOLOGY, cilt.4, 2018 (ESCI İndekslerine Giren Dergi)
- IV. **Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.**
Tural D., Serdengeçti S., Demirelli F. H., Öztürk T., İlvan Ş., Turna H., Ozguroglu M., Buyukunal E.
British journal of cancer, cilt.110, sa.8, ss.1968-1976, 2014 (Diğer Kurumların Hakemli Dergileri)
- V. **UNUSUAL PRESENTATION OF CERVICAL CARCINOMA METASTASIS TO THE BREAST: A CASE REPORT AND REVIEW OF THE LITERATURE**
Yetmen O., Oksuz D. C., Demirkiran F., Ozguroglu M., Calay Z., Atkovar G., Sahinler I.
JOURNAL OF BREAST HEALTH, cilt.8, sa.2, ss.92-96, 2012 (ESCI İndekslerine Giren Dergi)
- VI. **Serviks kanserinin memeye sıra dışı metastazı: Olgu sunumu ve literatür değerlendirilmesi.**
Yetmen Ö., ÇOLPAN ÖKSÜZ D., DEMİRKİRAN F., ÖZGÜROĞLU M., CALAY Z. Z., ATKOVAR G., ŞAHİNLER İ.
Meme Sağlığı Dergisi, sa.8, ss.92-96, 2012 (Diğer Kurumların Hakemli Dergileri)
- VII. **Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.**
SELÇUKBİRİCİK F., TURAL D., ELİCİN O., BERK S., ÖZGÜROĞLU M., BESE N., FERHANOĞLU B.

ISRN oncology, cilt.2012, ss.951816, 2012 (Diğer Kurumların Hakemli Dergileri)

- VIII. **Mide karsinomlarında postoperatif kemoradyoterapi tedavi sonuçları: Cerrahpaşa deneyimi**
ÇOLPAN ÖKSÜZ D., Eren M. F. , BEŞE F. N. , BÜYÜKÜNAL E., ÖZGÜROĞLU M., Mandel N. M. , TURNA Z. H. ,
DEMİRELLİ F. H. , SERDENGEÇTİ A. S. , ATKOVAR G., et al.
TÜRK ONKOLOJİ DERGİSİ, sa.25, ss.1-10, 2010 (Diğer Kurumların Hakemli Dergileri)
- IX. **The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpasa experience**
Oksuz D. C. , Eren M. F. , Bese N. S. , Buyukunal E., Ozguroglu M., Mandel N. M. , TURNA Z. H. , Demirelli F.,
Serdengecti S., Atkovar G., et al.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.25, sa.1, ss.1-10, 2010 (ESCI İndekslerine Giren Dergi)
- X. **Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma**
Beşe N. Ş. , Özgüroğlu M., Dervişoğlu S., Kanberoğlu K., Öber A.
Radiation Medicine - Medical Imaging and Radiation Oncology, cilt.24, sa.2, ss.150-153, 2006 (Diğer Kurumların Hakemli Dergileri)
- XI. **Pentoxifylline in the Treatment of Radiation-related Pelvic Insufficiency Fractures of Bone**
Beşe N. Ş. , Özgüroğlu M., Kamberoğlu K., Karahasanoglu T., Öber A.
Radiation Medicine - Medical Imaging and Radiation Oncology, cilt.21, sa.5, ss.223-227, 2003 (Diğer Kurumların Hakemli Dergileri)
- XII. **Uveal malign melanomlu olguların retrospektif değerlendirilmesi-tedavi yaklaşımı ve sonuçları**
ÖZGÜROĞLU M., Pazarlı H., ÖZARAS R., Demir G., Tahan V., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B.
AVICENA, cilt.1, ss.30-32, 1999 (Diğer Kurumların Hakemli Dergileri)
- XIII. **Kadınlarda primeri bilinmeyen aksiller karsinom metastazına yaklaşım: iki olgu bildirim**
ÖZGÜROĞLU M., Tahan V., ÖZARAS R., Demir G., Çerçel A., Demirelli F. H. , Mandel N. M. , Büyükinal E., Serdengeçti S., Berkarda B., et al.
Meme Hastalıkları Dergisi, cilt.5, ss.172-175, 1998 (Diğer Kurumların Hakemli Dergileri)
- XIV. **The effects of tamoxifen on endometrium of patients with breast cancer Meme kanserli hastalarda tamoksifen tedavisinin yapmış olduğu endometriyum değişiklikleri**
Kosebay D., Arvas M., Bese T., Demirkiran F., Mandel N., Ozguroglu M., Bese N., Ober A., Okkan S.
Jinekoloji ve Obstetrik Dergisi, cilt.10, sa.2, ss.68-73, 1996 (Diğer Kurumların Hakemli Dergileri)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)**
Lu S., Casarini I., Kato T., Cobo Dols M., Ozguroglu M., Zeng L., van der Gronde T., Saggese M., Ramalingam S.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31
- II. **Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials**
Ozguroglu M., Shitara K., Lee K., Fuchs C. S. , Chung H. C. , Di Bartolomeo M., Chao J., Wainberg Z. A. , Caglevic C., Kudaba I., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- III. **Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound**
Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- IV. **Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and**

homologous recombination repair (HRR) gene alterations

de Bono J. S. , Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K. N. , Sartor O., Agarwal N., Olmos D., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31

- V. **EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) \geq 50%**
Sezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., Ozguroglu M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- VI. **Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361**
Alva A., Csoszi T., Ozguroglu M., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., Morales Barrera R., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- VII. **Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study**
Baciarello G., Ozguroglu M., Mundle S. D. , Leitz G., Richarz U., Hu P., Chi K. N. , Fizazi K.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- VIII. **Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial**
Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F. , Spigel D. R. , Garassino M. C. , Reck M., Senan S., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- IX. **Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN**
Goldman J. W. , Garassino M. C. , Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., Trukhin D., Hochmair M. J. , Ozguroglu M., Ji J. H. , et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
- X. **KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma**
Yoon H., Fuchs C., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., et al.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31
- XI. **APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES**
Chowdhury S., Bjartell A., Agarwal N., Chung B. H. , Given R. W. , Pereira de Santana Gomes A. J. , Merseburger A. S. , Ozguroglu M., Juarez Soto A., Uemura H., et al.
Annual Meeting of the American-Urological-Association (AUA), Washington, Kiribati, 15 - 18 Mayıs 2020, cilt.203
- XII. **Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy**
Chao J., Fuchs C. S. , Shitara K., Tabernero J., Muro K., Van Cutsem E., Bang Y., De Vita F., Landers G. A. , Yen C., et al.
Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38
- XIII. **Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)**
Agarwal N., Chowdhury S., Bjartell A., Chung B. H. , Gomes A. J. P. d. S. , Given R. W. , Soto A. J. , Merseburger A. S. , Ozguroglu M., Uemura H., et al.
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38
- XIV. **PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic**

urothelial cancer (mUC)

Huddart R. A. , Siefker-Radtke A. O. , Balar A. V. , Bilen M. A. , Powles T., Bamias A., Castellano D., Khalil M. F. , Van der Heijden M. S. , Koshkin V. S. , et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38

- XV. **Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)**

Moehler M. H. , Dvorkin M., Ozguroglu M., Ryu M., Muntean A. S. , Lonardi S., Nechaeva M., Bragagnoli A. S. C. , Coskun H. S. , Gracian A. C. , et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38

- XVI. **Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease**

Ozguroglu M., Chowdhury S., Bjartell A., Uemura H., Chung B. H. , Agarwal N., Merseburger A. S. , Soto A. J. , Lopez-Gitlitz A., Bhaumik A., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38

- XVII. **PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations**

De Bono J. S. , Fizazi K., Saad F., Shore N. D. , Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Procopio G., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38

- XVIII. **Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience**

Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., Demirelli F. H. , Ozguroglu M.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30

- XIX. **First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN**

Ozguroglu M., Goldman J. W. , Reinmuth N., Chen Y., Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J. H. , Hochmair M. J. , et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, ss.66

- XX. **Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study**

Herbst R. S. , de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, ss.62-63

- XXI. **Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia**

Nishio M., Ji J. H. , Hotta K., Chiu C., Lee J., Azuma K., Kim S., Wu S., Dvorkin M., Trukhin D., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30

- XXII. **Three-year overall survival update from the PACIFIC trial**

Wu Y., Gray J. E. , Villegas A., Daniel D. B. , Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30

- XXIII. **Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study**

Chung B. H. , McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J. , Ozguroglu M., Juarez Soto A., Merseburger A. S. , Uemura H., Ye D., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30

- XXIV. **IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC**
Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z. G. , Geater S., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.915
- XXV. **Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)**
Barlesi F., Ozguroglu M., Vansteenkiste J. F. , Spigel D., Yang J. C. , Bajars M., Ruisi M., Manitz J., Park K.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30
- XXVI. **Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)**
Van Cutsem E., Amonkar M., Fuchs C. S. , Alsina M., Ozguroglu M., Bang Y., Chung H. C. , Muro K., Goekkurt E., Benson A., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.304
- XXVII. **IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)**
Grande E., Galsky M., Arranz Arijia J. A. , De Santis M., Davis I. D. , De Giorgi U. F. F. , Mencinger M., Kikuchi E., Garcia del Muro X., Gumus M., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.888-889
- XXVIII. **PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN**
Paz-Ares L., Goldman J. W. , Garassino M. C. , Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J. H. , Hochmair M. J. , Voitko O., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.928-929
- XXIX. **Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study**
de Bono J. S. , Fizazi K., Saad F., Shore N., Sandhu S. K. , Mehra N., Kolinsky M., Roubaud G., Ozguroglu M., Matsubara N., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.328-329
- XXX. **Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)**
Vansteenkiste J. F. , Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., Murakami S., Hui R., Lee K. H. , Cho B. C. , et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.592-593
- XXXI. **Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)**
Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Gomes A. J. P. D. S. , Chung B. H. , Ozguroglu M., Juarez Soto A.,

Merseburger A., Uemura H., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30

XXXII. A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Pauli C., Bochtler T., Mileschkin L., Baciarello G., Losa F., Ross J., Pentheroudakis G., Zarkavelis G., YALÇIN Ş., Ozguroglu M., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30

XXXIII. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged \geq 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Shitara K., Doi T., Hosaka H., Thuss-Patience P. C., Santoro A., Jimenez-Fonseca P., Longo F., Ozyilkan O., Cicin I., Park D., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

XXXIV. Three-year overall survival update from the PACIFIC trial.

Gray J. E., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H., Cho B. C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

XXXV. First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.

Planchard D., Cho B. C., Gray J. E., Paz-Ares L. G., Ozguroglu M., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

XXXVI. First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Chi K. N., Agarwal N., Bjartell A., Chung B. H., Gomes A. J. P. d. S., Given R. W., Soto A. J., Merseburger A. S., Ozguroglu M., Uemura H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

XXXVII. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)

Woo H., Fizaz K., Sulur G., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B., Ozguroglu M., Ye D., et al.

Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Brisbane, Avustralya, 13 - 16 Nisan 2019, cilt.123, ss.27-28

XXXVIII. Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).

Fizazi K., Namphuong Tran N. T., Fein L. E., Matsubara N., Antolin A. R., Ozguroglu M., Ye D., Feyerabend S., Protheroe A., Sulur G., et al.

ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Kostarika, 28 Şubat - 02 Mart 2019, cilt.37

XXXIX. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Raben D., Faivre-Finn C., Spigel D., Daniel D., Villegas A., Vincente D., Hui R., Carpeno J. d. C., Murakami S., Paz-Ares L., et al.

60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Kuzey Mariana

Adaları, 21 - 24 Ekim 2018, cilt.102, ss.1607-1608

- XL. **Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer**
Lin C., Taylor M., Boni V., Brunsvig P. F., Geater S. L., Salvagni S., Garrido Lopez P., Ozguroglu M., Sriuranpong V., Ponce Aix S., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.413
- XLl. **LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)**
Matsubara N., Chi K. N., Ozguroglu M., Rodriguez Antolin A., Feyerabend S., Fein L., Alekseev B. Y., Suler G., Protheroe A., Li S., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29
- XLII. **Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer**
Kato K., Shah M. A., Enzinger P. C., Bennouna J., Shen L., Adenis A., Sun J., Cho B. C., Ozguroglu M., Kojima T., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29
- XLIII. **Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC**
Faivre-Finn C., Spigel D. R., Senan S., Langer C. J., Raben D., Perez B., Ozguroglu M., Daniel D., Villegas A., Vicente D., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.488
- XLIV. **KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer**
Shitara K., Ozguroglu M., Bang Y. J., Di Bartolomeo M., Mandala M., Ryu M. H., Fornaro L., Olesinski T., Caglevic C., Chung H., et al.
ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 20 - 23 Haziran 2018, cilt.29
- XLV. **A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress**
Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., Sun J., Cho B., Ozguroglu M., Kojima K., et al.
ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 20 - 23 Haziran 2018, cilt.29
- XLVI. **An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting**
Cicin I., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Slim B. A., Uslu R., Errihani H., Alsalef K., Belbaraka R., et al.
11th European Breast Cancer Conference (EBCC), Barcelona, İspanya, 21 - 23 Mart 2018, cilt.92
- XLVII. **JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).**
Moehler M. H., Ryu M., Lee K., Coskun H. S., Wong R., Ozguroglu M., Chung H., Poltoratsky A., Tsuji A., Yen C., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36
- XLVIII. **PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer**
Antonia S. J., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H., de Wit M., et al.
59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO), California, Amerika Birleşik Devletleri, 24 - 27 Eylül 2017, cilt.99, ss.1314-1315
- XLIX. **PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC**
Paz-Ares L., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K. H., de Wit M., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28

- L. **JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+non-small-cell lung cancer (NSCLC)**
Reck M., Yang C., Postmus P. E. , Barlesi F., Font E. F. , Thomas M., Kim T. M. , Dols M. C. , Skuladottir H., Park K., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28
- LI. **Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4**
Bachelot T., Royce M., Villanueva C., Melo Cruz F., Hegg R., Falkson C., Jeong J., Srimuninnimit V., Arce C. H. , Ridolfi A., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28
- LII. **LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer**
Fizazi K., Tran N., Fein L. E. , Matsubara N., Antolin A. R. , Alekseev B. Y. , Ozguroglu M., Ye D., Feyerabend S., Protheroe A., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35
- LIII. **Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.**
Cardoso F., Villanueva C., Royce M., Cruz F., Debled M., Hegg R., Toyama T., Falkson C. I. , Jeong J., Srimuninnimit V., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35
- LIV. **Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial**
Villanueva C., Tsugawa K., Toyama T., Noh W., Jeong J., Cardoso F., Sriuranpong V., Srimuninnimit V., Ozguroglu M., Kendall S., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2016, cilt.77
- LV. **TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)**
Chi K. N. , Chowdhury S., Radziszewski P., Lebret T., Ozguroglu M., Sternberg C., Sims R. B. , Yu M., Naini V., Darif M., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27
- LVI. **BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)**
Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., Hegg R., Debled M., Gradishar W. J. , Manlius C., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27
- LVII. **Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.**
Reck M., DeGreen H. P. , Rose A. L. , Pavlakis N., Derjcke S. M. , Radic J., Jeppesen N., Thomas M., Losonczy G., Kalinka-Warzocho E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- LVIII. **Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3**

Isaacs C., O'Regan R., Xu B., Masuda N., Arena F., Yap Y., Papal Z., Lang I., Armstrong A., Lerzo G., et al.
38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 12 Aralık
2015, cilt.76

- LIX. **Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis**
Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., Leung K. C. , Butt M., Silva A., Castillo L., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- LX. **Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting**
Oudard S., Angelergues A., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., Ozguroglu M., Flechon A., Guillot A., Le Moulec S., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- LXI. **Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel**
Angelergues A., Bellmunt J., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., Ozguroglu M., Flechon A., Guillot A., Le Moulec S., et al.
European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 25 - 29 Eylül 2015, cilt.51
- LXII. **Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study**
Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., Caty A., Dujardin C., Auclin E., Tartour E., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- LXIII. **Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey**
Celik I., Mandel N. M. , Gokmen E., Unal O. U. , Sevinc A., Coskun H. S. , Buyukberber S., Abali H., Ozguroglu M., Utkan G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- LXIV. **Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).**
Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzebec P., Massard C., et al.
Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32
- LXV. **ER/PR/HER2 receptor discordance between primary tumors and corresponding axillary metastases in curatively resected node positive breast cancer patients**
Ozturk M., Turna H., Aydin O., Tural D., Demirelli F., Ozguroglu M., Buyukunal E., Ilvan S., Serdengecti S.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49
- LXVI. **Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies**
Tural D., Demirelli F., Serdengecti S., ÖZTÜRK T., Ilvan S., Turna H., Ozguroglu M., Buyukunal E.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49
- LXVII. **Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).**
O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G. H. M. , Wilks S., Isaacs C., Xu B., Masuda N., Arena F. P. , et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31

Mayıs - 04 Haziran 2013, cilt.31

- LXVIII. **Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter**
Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31
- LXIX. **IMPACT OF CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) ON OVERALL SURVIVAL (OS) AT 2 YRS AND IN PATIENTS (PTS) WITH AGGRESSIVE DISEASE: POST-HOC ANALYSES OF TROPIC TRIAL**
Oudard S., de Bono J. S., Ozguroglu M., Hansen S., Machiels J., Kocak I., Gravis G., Bodrogi I., Shen L., Sartor A. O.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012, cilt.23, ss.307-308
- LXX. **Thromboembolic complications in cancer patients.**
Yenidunya G., Turna H., Ozturk M. A., Tural D., Selcukbiricik F., Yildiz O., Ozguroglu M., Demirelli F., Buyukunal E., Serdengeçti S.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30
- LXXI. **A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.**
Bavbek S. E., Malik Z. I., Di Lorenzo G., Scholz H., van Oort I. M., Siobhan Ng S. N., Ozguroglu M., Gerritsen W. R., Mueller S., Marttila T., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30
- LXXII. **NOD POZİTİF MEME KANSERLERİNDE PRİMER TUMÖR VE AKSİLLER METASTAZIN ER, PR VE HER2 EKSPRESYONU AÇISINDAN KARŞILAŞTIRILMASI**
ÖZTÜRK M. A., AYDIN Ö., İLVAN Ş., TURNA Z. H., TURAL D., YILDIZ Ö., ÖZGÜROĞLU M., BÜYÜKÜNAL E., SERDENGEÇTİ S.
4. TIBBİ ONKOLOJİ KONGRESİ, Antalya, Türkiye, 21 - 25 Mart 2012, ss.103
- LXXIII. **Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer**
Turhal D., Ozturk M. A., Yildiz O., Selcukbiricik F., Elicin O., Erguney S., Ozguroglu M.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47
- LXXIV. **Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer**
Turna Z. S., Ozturk M. A., Tural D., Biricik F. S., Yildiz O., Ozguroglu M., Demirelli F., Mandel N. M., Buyukunal E., Serdengeçti S.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47
- LXXV. **KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?**
Selcukbiricik F., Yildiz O., Tural D., Ozturk M. A., Demir G., Ozguroglu M., Erdamar S., Buyukunal E., Mandel N. M., Serdengeçti S.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47
- LXXVI. **Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen - Interim Analysis Results From an Ongoing Compassionate-use Programme**
Heidenreich A., Scholz H. J., van Oort I., Bavbek S., Mueller S., Ozguroglu M., Albers P., Gschwend J., Ecstein-Fraisse E.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47

- LXXVII. **INCREASING ROLE OF METASTASECTOMY IN METASTATIC BREAST CANCER PATIENTS: WHO BENEFITS MORE**
Selcukbiricik F., Ozguroglu M., Öztürk M. S. , Turna H., Tural D., Yildiz O., Demirelli F., Serdengeçti S.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.111
- LXXVIII. **THE EFFECTS OF PATIENT AND TUMOR CHARECTERISTICS AND TREATMENT MODALITIES ON PROGNOSIS OF PATIENTS WITH UVEAL MELANOMA**
Tural D., Ozguroglu M., Turna H., Selcukbiricik F., Ozturk M. A. , Sevinc M., Demirkesen C., Sarici A., Pazarli H., Serdengeçti S.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.406
- LXXIX. **CABAZITAXEL PLUS PREDNISONE/PREDNISOLONE SIGNIFICANTLY INCREASES OVERALL SURVIVAL COMPARED TO MITOXANTRONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: FINAL RESULTS WITH UPDATED OVERALL SURVIVAL OF A MULTINATIONAL PHASE III TRIAL (TROPIC)**
Oudard S. M. , De Bono J. S. , Ozguroglu M., Hansen S., Machiels J., Shen L., Gupta S., Sartor A. O.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.272
- LXXX. **Is there any future of prophylactic cranial irradiation in adenocarcinoma of the lung?**
Ozguroglu M., Turna H., Sevinc M., Karaaslan S., Gursu U. R.
15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Almanya, 20 - 24 Eylül 2009, cilt.7, ss.534
- LXXXI. **The effects of prognostic factors on the first recurrence patterns of breast cancer**
Turna H., Ozguroglu M., Demir G., Mandel N., Ilvan S., Calay Z., Buyukunal E., Serdengeçti S.
15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Almanya, 20 - 24 Eylül 2009, cilt.7, ss.312
- LXXXII. **AWARENESS OF CANCER DIAGNOSIS IN TURKISH CANCER PATIENTS AND ATTITUDES OF PHYSICIANS AND NURSES TOWARDS DISCLOSURE OF THE DIAGNOSIS**
Sayilir A., Ozguroglu M., Turna H.
33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.263
- LXXXIII. **CHARACTERISTICS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS**
Turna H., Ozguroglu M., Guersu R. U. , Karaaslan S., Yildiz O., Yanmaz M. T.
33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.256-257
- LXXXIV. **MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE**
Ozguroglu M., Mansutti M., Kerr R., Awada A., Rha S. Y. , Im Y. H. , Perez Manga G., Germann N., Fumoleau P.
33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.69
- LXXXV. **Trastuzumab beyond progression in metastatic breast cancer**
Yanmaz M. T. , Ozguroglu M., Ozturk B., Uygun K., Basaran G., Turna H., Yildiz O., Baran A., Demir G., Buyukunal E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.77
- LXXXVI. **Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty**
Yildiz I., Mandel N. M. , Demir G., Ozguroglu M., Toptas T., Buyukunal E., Serdengeçti S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.164
- LXXXVII. **Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)**
Ozguroglu M., Evrensel T., Er O., Turna H., Yanmaz T., Yildiz O., Mandel N., Serdengeçti S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.225
- LXXXVIII. **The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma**

Bese N., Yildirim A., Ober A., Ozguroglu M., Mandel N., Demir G., Demirelli F., Serdengeçti S., Buyukunal E.
23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam,
Hollanda, 24 - 28 Ekim 2004, cilt.73

LXXXIX. Gastric cancer in Turkey: A single center experience of 683 cases

Demir G., Buyukunal E., Kizilkilic E., Ozguroglu M., Mandel N., Demirelli F., Serdengeçti S.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08
Haziran 2004, cilt.22

XC. Is the incidence of anal canal cancers different in Moslem societies?

Cabuk D., Yumuk P., Abacioglu U., Demir G., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08
Haziran 2004, cilt.22

XCI. The acute phase proteins in cancer patients

Bolayirli I., Ozguroglu M., Balci H., Orhanoglu T., Hacibekiroglu M.

56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los-Angeles, Şili, 25 - 29 Temmuz 2004,
cilt.50

XCII. Significance of serum beta-2 microglobulin in epithelial ovarian cancer

ÖZGÜROĞLU M., Tahan V., Demir G., ÖZARAS R., Demirelli F. H. , Mandel N. M. , Büyükinel E., Serdengeçti S.,
Berkarda B.

35th Annual Meeting , American Society of Clinical Oncology, Atlanta, Amerika Birleşik Devletleri, 15 - 18 Mayıs
1999, cilt.1, ss.382

XCIII. Uveal Malign Melanomlu Olguların Retrospektif Değerlendirilmesi-tedavi Yaklaşımı ve Sonuçları

ÖZGÜROĞLU M., Demir G., ÖZARAS R., Tahan V., Pazarlı H., Demirelli F. H. , Mandel N. M. , Büyükinel E., Serdengeçti
S., Berkarda B.

XIII. Ulusal Kanser Kongresi, Antalya, Türkiye, 27 Nisan - 01 Mayıs 1999, cilt.1, ss.310

XCIV. Chemoimmunotherapy protocol in patients with advanced gastric cancer

Demir G., Ozguroglu M., Belentepe S., Demirelli F., Mandel N., Buyukunal E., Serdengeçti S., Berkarda B.

2nd Congress of the Balkan-Union-of-Oncology, İzmir, Türkiye, 10 - 14 Eylül 1998, ss.407-411

XCV. THE ROLE OF LOCAL RADIATION THERAPY IN NEOADJUVANT PROTOCOL OF OSTEOSARCOMA

Uzel M., HIZ V. M. M. , AYDINGÖZ Ö., Okkan S., KOCA S. S. , Molinas N., ÖZGÜROĞLU M., DERVİŞOĞLU S., Girişken G.,
Kanberoglu K.

2ND OSTEOSARCOMA RESEARCH CONFERENCE ABSTRACT BOOK, İtalya, 1 - 04 Kasım 1996, ss.21

Desteklenen Projeler

2012 - 2012	Meme kanserinde östrojen reseptörü, progesteron reseptörü ve Her 2 ekspresyonunun primer tümör ve metastazdaki durumunun belirlenmesi ve tedavi planı üzerine etkisi, Yükseköğretim Kurumları Destekli Proje
-------------	--

Bilimsel Kuruluşlardaki Üyelikler / Görevler

2017 - Devam Ediyor	FACULTY MEMBER of genitourinary cancers in ESMO, Danışma Kurulu Üyesi
2013 - Devam Ediyor	BOLERO 4 ÇALIŞMASINDA STEERING COMMITTE ÜYELİĞİ, Yönetim Kurulu Üyesi
2012 - Devam Ediyor	PROXIMA ÇALIŞMASINDA STEERING COMMITTEE ÜYELİĞİ, Yönetim Kurulu Üyesi
2021 - 2021	ESMO 2021, Bilim Kurulu Üyesi

Bilimsel Danışmanlıklar

2020 - Devam Ediyor	Kurum veya Organizasyonlar İçin Yapılan Danışmanlık, MSD
2020 - Devam Ediyor	Kurum veya Organizasyonlar İçin Yapılan Danışmanlık, MSD

2018 - Devam Ediyor	Kurum veya Organizasyonlar İçin Yapılan Danışmanlık, JANSSEN
2013 - Devam Ediyor	Bilimsel Projeler İçin Yapılan Danışmanlık, MEME KANSERİ ÇALIŞMASI
2012 - Devam Ediyor	Bilimsel Projeler İçin Yapılan Danışmanlık, PROSTAT KANSERİ ÇALIŞMASI
2020 - 2023	Kurum veya Organizasyonlar İçin Yapılan Danışmanlık, BAYER

Etkinlik Organizasyonlarındaki Görevler

14 Eylül 2021	Özgüroğlu M., ESMO, Bilimsel Kongre / Sempozyum Organizasyonu, Paris, Fransa
---------------	--

Davetli Kongre ve Sempozyum Faaliyetleri

2019	ESMO-IO, Davetli Konuşmacı, Geneve, İsviçre
------	---

Davetli Konuşmalar

Kasım 2020	PROFOUND STUDY, Seminer, Amerika Birleşik Devletleri
------------	--

Ödüller

Ekim 2004	best poster in ESMO meeting -pain in cancer patients, ESMO
Temmuz 1999	1999 yılındaki SCI ve SCIE kapsamındaki dergilerde uluslararası yayın sıralamasında birincilik ödülü, istanbul üniversitesi